Michael Wichroski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael Wichroski has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Abigail E. Witt
Research and Development, Bristol Myers Squibb Company, Cambridge, Massachusetts
14 shared publications - Dana Banas
Research and Development, Bristol Myers Squibb Company, Lawrenceville, New Jersey
14 shared publications - Joelle Onorato
Research and Development, Bristol Myers Squibb Company, Lawrenceville, New Jersey
14 shared publications - Joseph L. Benci
Research and Development, Bristol Myers Squibb Company, Lawrenceville, New Jersey
14 shared publications - Louis Chupak
Dunad Therapeutics , CIC Cambridge, 1 Broadway
14 shared publications - Rakeeb Kureshi
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA
14 shared publications
Latest Publications
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Fig. S1. BMS-986408 DGK family selectivity and activity and in T cell functional assays.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Fig. S1. BMS-986408 DGK family selectivity and activity and in T cell functional assays.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Fig. S2. Additional BMS-986408 mechanism of action data.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Fig. S2. Additional BMS-986408 mechanism of action data.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Table S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Table S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Fig. S5. Phosphoproteomics analysis of DGKα/ζ dual- and mono- inhibition.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Fig. S5. Phosphoproteomics analysis of DGKα/ζ dual- and mono- inhibition.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Fig. S7. Additional BMS-986408/CAR-T combination data.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Fig. S7. Additional BMS-986408/CAR-T combination data.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Table S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Table S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Table S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Table S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Fig. S3. Antigen specific T cell response in the CT26 model.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Fig. S3. Antigen specific T cell response in the CT26 model.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Table S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Table S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Fig. S4. Mono-selective DGKα and DGKζ inhibitor characterization.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Fig. S4. Mono-selective DGKα and DGKζ inhibitor characterization.